Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) from a sell rating to a hold rating in a research note published on Tuesday morning.

A number of other equities research analysts have also issued reports on the stock. Roth Mkm increased their price objective on shares of Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the company a buy rating in a report on Tuesday, December 19th. Brookline Capital Management downgraded Cyclacel Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, December 19th.

Cyclacel Pharmaceuticals Stock Up 5.6 %

Shares of NASDAQ:CYCC opened at $2.07 on Tuesday. The firm’s 50 day moving average price is $2.43 and its 200-day moving average price is $4.25. The stock has a market capitalization of $1.74 million, a PE ratio of -0.08 and a beta of 0.56. Cyclacel Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $13.20.

Institutional Trading of Cyclacel Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CYCC. HRT Financial LP purchased a new stake in Cyclacel Pharmaceuticals in the fourth quarter worth about $27,000. Virtu Financial LLC purchased a new stake in Cyclacel Pharmaceuticals in the second quarter worth about $33,000. Renaissance Technologies LLC purchased a new stake in Cyclacel Pharmaceuticals in the second quarter worth about $68,000. Two Sigma Investments LP purchased a new stake in Cyclacel Pharmaceuticals in the third quarter worth about $98,000. Finally, Millennium Management LLC purchased a new stake in Cyclacel Pharmaceuticals in the second quarter worth about $113,000. 23.58% of the stock is currently owned by institutional investors.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.